

Tilmicosin and Monensin Medicated Cattle Feed – BRD and Feed Efficiency

Type B Medicated Feed

CAUTION: Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian.

Do not Feed Undiluted

INDICATIONS

For improved feed efficiency and control of bovine respiratory disease (BRD) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, and *Histophilus somni* in groups of cattle fed in confinement for slaughter, where active BRD has been diagnosed in at least 10% of the animals in the group.

ACTIVE DRUG INGREDIENTS

Tilmicosin (as tilmicosin phosphate) ^c	up to 36,300 grams per ton ^{*,a}
Monensin, USP ^d	up to 80,000 grams per ton ^{*,b}

GUARANTEED ANALYSIS

Crude Protein, not less than	%
Non-Protein Nitrogen (NPN) ¹ , not more than	%
Crude Fat, not less than	%
Crude Fiber, not more than	%
Calcium, not less than	%
Calcium, not more than	%
Phosphorus, not less than	%
Salt ² , not less than	%
Salt ² , not more than	%
Sodium ³ , not less than	%
Sodium ³ , not more than	%
Potassium, not less than	%
Vitamin A ^{2,4} , not less than	I.U./lb

¹When added.

²If added.

³Shall be guaranteed only when total sodium exceeds that furnished by the maximum salt guarantee.

⁴Other than precursors of Vitamin A.

INGREDIENTS

Each ingredient must be named in accordance with the names and definitions adopted by the Association of American Feed Control Officials (AAFCO).

MIXING DIRECTIONS

Thoroughly mix this Type B medicated feed containing up to 36,300 g tilmicosin per ton and up to 80,000 g monensin per ton to prepare a complete Type C medicated feed containing 568 to 757 g tilmicosin per ton on a 100% dry matter basis (511.2 to 681.3 g per ton on a 90% dry matter basis) and 5 to 40 g monensin per ton on a 90% dry matter basis (5.6 to 44.4 g per ton on a 100% dry matter basis). No additional improvement in feed efficiency has been shown from feeding monensin at levels greater than 30 g per ton on a 90% dry matter basis (360 mg monensin per head per day). Some examples are listed in the table below.

Type B Medicated feed to Type C Medicated feed (100% Dry Matter Basis)

Tilmicosin concentration in Type B (g/ton)	Monensin concentration in Type B (g/ton)	Amount of Type B Medicated Feed to add per ton (lbs)	Resulting concentration in Type C Medicated Feed (g/ton)
30,280	400	50	757 (tilmicosin) 10 (monensin)
30,280	1000	50	757 (tilmicosin) 25 (monensin)
30,280	1600	50	757 (tilmicosin) 40 (monensin)
22,720	400	50	568 (tilmicosin) 10 (monensin)
22,720	1000	50	568 (tilmicosin) 25 (monensin)
22,720	1600	50	568 (tilmicosin) 40 (monensin)
7570	100	200	757 (tilmicosin) 10 (monensin)
7570	250	200	757 (tilmicosin) 25 (monensin)
7570	400	200	757 (tilmicosin) 40 (monensin)
5680	100	200	568 (tilmicosin) 10 (monensin)
5680	250	200	568 (tilmicosin) 25 (monensin)
5680	400	200	568 (tilmicosin) 40 (monensin)

CAUTION

Use only in cattle fed in confinement for slaughter.

Do not allow horses or other equines access to feeds containing tilmicosin or monensin. Ingestion of monensin by horses has been fatal. Monensin medicated cattle feeds are safe for use in cattle only. Consumption by unapproved species may result in toxic reactions. The safety of tilmicosin has not been established in cattle intended for breeding purposes.

Feeding undiluted or mixing errors resulting in high concentrations of monensin has been fatal to cattle. Must be thoroughly mixed in feeds before use. Do not exceed the levels of monensin recommended in the feeding directions, as reduced average daily gains may result.

To assure both food safety and responsible use in cattle, the treatment of cattle with this medicated feed is required to be initiated within the first 45 days of the production period. The treatment should not occur concurrent with or following administration of an injectable macrolide, or within 3 days following administration of a non-macrolide injectable BRD therapy

Tilmicosin medicated feed treatment has not been evaluated in cattle with severe clinical disease. Cattle with severe clinical illness should be evaluated for individual treatment with an alternative non-macrolide therapy.

Complete Type C medicated feeds containing tilmicosin should not be pelleted. Do not use in any feeds containing bentonite, cottonseed meal, or cottonseed hulls. Bentonite, cottonseed meal, or cottonseed hulls in feeds may affect the efficacy of tilmicosin.

The expiration date for a tilmicosin Veterinary Feed Directive (VFD) for cattle must not exceed 45 days from the time of issuance. VFDs for tilmicosin phosphate shall not be refilled.

WARNINGS

RESIDUE WARNING: Cattle: Cattle intended for human consumption must not be slaughtered within 28 days of the last treatment with tilmicosin.

Tilmicosin is not approved for use in female dairy cattle 20 months of age or older. Use in these cattle may cause drug residues in milk. Tilmicosin and monensin are not approved for use in calves intended to be processed for veal. A withdrawal period has not been established in pre-ruminating calves.

Approved by FDA under ANADA # 200-654

MANUFACTURED BY
Bluebird Feed Company
Any town, USA 12345

Net Weight: _____ lb (_____ kg)

Lot No. _____

For emergency medical information, to report an adverse effect, or for technical service call:
1-877-426-7765.

*Final printed label must bear a single drug concentration.

^a100% dry matter basis.

^b90% dry matter basis.

^cSourced from Tilmovet[®], ANADA# 200-509

^dSourced from Monovet[®], ANADA# 200-639

Tilmovet and Monovet are registered trademarks of Huvepharma EOOD.

